Newly Diagnosed Central Serous Chorioretinopathy: Demographics and Epidemiology from the IRIS Registry (Intelligent Research in Sight)
Kapil Mishra, MD
Mishra, Kapil1,2; Brant, Arthur1,2; Pershing, Suzann1,3; Perlroth, Ashton1,2; Bair, Henry1,2; Xu, Christine1,2; Do, Diana V.1,2
1. Byers Eye Institute, Stanford University School of Medicine, Stanford, CA, United States
2. Byers Eye Institute, Stanford University, Spencer Center for Vision Research, Palo Alto, CA, United States
3. VA Palo Alto Health Care System, Palo Alto, CA, United States
Purpose: To determine demographics and visual acuity for patients with newly diagnosed central serous chorioretinopathy (CSCR) as captured in the IRIS Registry.
Methods: We identified patients with a new diagnosis of CSCR between 2017 and 2018 in the IRIS Registry. We investigated patient characteristics (age, sex, and race/ethnicity) associated with CSCR, and visual acuity (VA) at time of first diagnosis and routine follow-up visits. We processed multivariate regressions to analyze the odds of developing CSCR relative to all patients in the IRIS Registry database.
Results: 28,323 patients were newly diagnosed with CSCR between 2017 and 2018 in the IRIS Registry. The majority of patients with new CSCR were male (68.54%), and the decade with the most CSCR diagnoses was 51-60 years (23.68%). Mean VA at time of diagnosis was 0.29 logMAR (about 20/40) which decreased onlyslightly to 0.33 logMAR 1 year following diagnosis. Compared to patients in the IRIS Registry without CSCR, patients with CSCR were more likely to be of Asian (Odds ratio (OR) 1.65, p < 0.001) or Hispanic descent (OR1.5, p < 0.001) using White as a reference, and were more likely to have Commercial (OR 1.12, p <0.001) or Military (OR 1.29, p <0.001) insurance compared to Medicare, Medicaid (using no insurance as a reference).
Conclusions: According to the IRIS Registry, patients with newly diagnosed CSCR were most commonly middle-aged male, of Asian or Hispanic descent, and with commercial or military insurance. Initial VA at diagnosis was 20/40, and this was relatively stable 1 year following diagnosis.